A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart

International Immunopharmacology

Volumn 3, Issue 10-11, 2003, Pages 1511-1518

  Lagneux, Caroline ^a,b   Adam, Albert ^a   Lamontagne, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Cannabinoids; Cardioprotection; Kinins; Myocardial ischemia reperfusion; Nitric oxide; Prostaglandins

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; CLOTRIMAZOLE; ICATIBANT; INDOMETACIN; NITRIC OXIDE SYNTHASE INHIBITOR; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISOLATED HEART; MALE; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

EID: 0042427567     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00177-2     Document Type: Article

References (36)

1. Bhoola K.D., Figueroa C.D., Worthy K. Bio regulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1992;1-80.
2. 1 receptors for kinins. Pharmacol. Rev. 50:1998;357-386.
3. Chahine R., Adam A., Yamaguchi N., Gaspo R., Regoli D., Nadeau R. Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br. J. Pharmacol. 108:1993;318-322.
4. Bouchard J.F., Chouinard J., Lamontagne D. Role of kinins in the endothelial protective effect of ischaemic preconditioning. Br. J. Pharmacol. 123:1998;413-420.
5. Linz W., Wohlfart P., Scholkens B.A., Malinski T., Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc. Res. 43:1999;549-561.
6. Randall M.D., Kendall D.A. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur. J. Pharmacol. 24(335):1997;205-209.
7. Piomelli D., Giuffrida A., Calignano A., Rodríguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21:2000;218-223.
8. Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther. 281:1997;1030-1037.
9. Varga K., Lake K.D., Huangfu D., Guyenet P.G., Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension. 28:1996;682-686.
10. Wagner J.A., Hu K., Bauersachs J., Karcher J., Wiesler M., Goparaju S.K.et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 38:2001;2048-2054.
11. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C.et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 22:1994;240-244.
12. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C.et al. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 84:1998;644-650.
13. Linz W., Wiemer G., Scholkens B.A. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Diabetes. 45:1996;S51-S58.
14. Bugge E., Ytrehus K. Bradykinin protects against infarction but does not mediate ischemic preconditioning in the isolated rat heart. J. Mol. Cell. Cardiol. 28:1996;2333-2341.
15. Ribuot C., Yamaguchi N., Godin D., Jette L., Adam A., Nadeau R. Intracoronary infusion of bradykinin: effects on noradrenaline overflow following reperfusion of ischemic myocardium in the anesthetized dog. Fundam. Clin. Pharmacol. 8:1994;532-538.
16. Martorana P.A., Kettenbach B., Breipohl G., Linz W., Scholkens B.A. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur. J. Pharmacol. 182:1990;395-396.
17. Linz W., Wiemer G., Scholkens B.A. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J. Mol. Cell. Cardiol. 24:1992;909-919.
18. Yang X.P., Liu Y.H., Mehta D., Cavasin M.A., Shesely E., Xu J.et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ. Res. 88:2001;1072-1079.
19. Ebrahim Z., Yellon D.M., Baxter G.F. Bradykinin elicits "second window" myocardial protection in rat heart through an NO-dependent mechanism. Br. J. Pharmacol. 281:2001;H1458-H1464.
20. Tschope C., Heringer-Walther S., Walther T. Regulation of the kinin receptors after induction of myocardial infarction: a mini-review. Braz. J. Med. Biol. Res. 33:2000;701-708.
21. Mazenot C., Loufrani L., Henrion D., Ribuot C., Muller-Esterl W., Godin-Ribuot D. Endothelial kinin B(1)-receptors are induced by myocardial ischaemia-reperfusion in the rabbit. J. Physiol. 530:2001;69-78.
22. Pesquero J.B., Araujo R.C., Heppenstall P.A., Stucky C.L., SilvaJr J.A., Walther T.et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8140-8145.
23. Regoli D. Toward a new anti-inflammatory and analgesic agent. Proc. Natl. Acad. Sci. U. S. A. 97:2000;7676-7677.
24. Marin-Castano M.E., Schanstra J.P., Neau E., Praddaude F., Pecher C., Ader J.L.et al. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation. 105:2002;627-632.
25. Ignjatovic T., Tan F., Brovkovych V., Skidgel R.A., Erdos E.G. Novel mode of action of angiotensin I converting enzyme inhibitors. J. Biol. Chem. 277:2002;16847-16852.
26. 9bradykinin-induced coronary vasodilation. Br. J. Pharmacol. 128:1999;275-282.
27. Yayama K., Nagaoka M., Takano M., Okamoto H. Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes. Biochim. Biophys. Acta. 149:2000;69-77.
28. Millette E., De Champlain J., Lamontagne D. Altered coronary dilation in deoxycorticosterone acetate-salt hypertension. J. Hypertens. 18:2000;1783-1793.
29. Fulton D., Giff M.C., Quilley J. Pharmacological evaluation of an epoxyde as the putative hyperpolarizing factor mediating the nitric oxide independent vasodilator effect of bradykinin in the rat heart. J. Physiol. Parmacol. Ther. 287:1998;497-503.
30. Rastaldo R., Paolocci N., Chiribiri A., Penna C., Gattullo D., Pagliaro P. Cytochrome P-450 metabolite of arachidonic acid mediates bradykinin induced negative inotropic effect. Am. J. Physiol. 280:2001;H2823-H2832.
31. Randall M.D., Alexander S.P., Bennett T., Boyd E.A., Fry J.R., Gardiner S.M.et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun. 229:1996;114-120.
32. Smith S.R., Terminelli C., Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther. 293:2000;136-150.
33. 1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346(Pt 3):2000;835-840.
34. Lépicier P., Bouchard J.-F., Lagneux C., Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol. 182:2003;805-815.
35. Lagneux C., Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol. 132:2001;793-796.
36. Joyeux M., Arnaud C., Godin-Ribuot D., Demenge P., Lamontagne D., Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res. 55:2002;619-625.